- Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of 2024
- Plan to initiate a Phase 2 trial in Graves’ Disease in early 2023 with initial results expected in the second half of 2023
- Immunovant expects a robust cadence of data every half year beginning in the second half of 2023 through the first half of 2025, including multiple clinical readouts in CIDP, Graves’ Disease, Myasthenia Gravis (MG), and Thyroid Eye Disease (TED)
- Company management will host an investor webcast today at 8 AM ET that can be accessed here.
Novavax’s COVID-19 Shot Just In Time, Optimism Surrounds As Demand Picks Up Momentum
Tuesday, the FDA granted an emergency use nod to Novavax Inc's (NASDAQ: NVAX) COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) for active immunization to prevent COVID-19 in
